The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 dose escalation study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC), in patients (pts) with solid tumors likely to express NaPi2b.
 
Anthony W. Tolcher
Employment - Next Oncology; START
Leadership - Symphogen
Consulting or Advisory Role - AbbVie (Inst); Adagene (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aro BioTX (Inst); Ascentage Pharma (Inst); Aximmune (Inst); Bayer (Inst); BioInvent (Inst); BioInvent (Inst); Birdie Bio (Inst); Boston Biomedical (Inst); EMD Serono (Inst); Forbius (Inst); HBM Partners (Inst); Ignyta (Inst); Immunome (Inst); Immunome (Inst); Jazz Pharmaceuticals (Inst); Mekanistic Therapeutics (Inst); Nanobiotix (Inst); NBE Therapeutics (Inst); Nuvalent, Inc. (Inst); Pelican Therapeutics (Inst); Pfizer (Inst); Pierre Fabre (Inst); Ridgeway (Inst); Scientex (Inst); Seagen (Inst); Sesen Bio (Inst); Symphogen (Inst); Syneos Health (Inst)
Research Funding - AbbVie (Inst); Adagene (Inst); ADC Therapeutics (Inst); Aminex (Inst); Arrys Therapeutics (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Birdie Biomedical (Inst); CStone Pharmaceuticals (Inst); Deciphera (Inst); GlaxoSmithKline (Inst); Inhibrx (Inst); Innate Pharma (Inst); Kiromic (Inst); Mersana (Inst); Naturewise (Inst); NextCure (Inst); Nitto BioPharma (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Symphogen (Inst); Syndax (Inst); Tizona Therapeutics, Inc. (Inst); Zymeworks (Inst)
 
Susanna Varkey Ulahannan
Consulting or Advisory Role - Bayer; Exelixis
Research Funding - Abbvie (Inst); ArQule (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); CicloMed (Inst); G1 Therapeutics (Inst); Incyte (Inst); Klus Pharma (Inst); Merck (Inst); Mersana (Inst); OncoMed (Inst); Pfizer (Inst); Regeneron (Inst); Revolution Medicines (Inst); Takeda (Inst)
 
Kyriakos P. Papadopoulos
Consulting or Advisory Role - ArQule (Inst); Bayer (Inst)
Research Funding - 3D Medicines (Inst); Abbvie (Inst); ADC Therapeutics (Inst); Amgen (Inst); ARMO BioSciences (Inst); ArQule (Inst); Calithera Biosciences (Inst); Curegenix (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Formation Biologics (Inst); Incyte (Inst); Jounce Therapeutics (Inst); MabSpace Biosciences (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); OncoMed (Inst); Peloton Therapeutics (Inst); Regeneron (Inst); Sanofi (Inst); Syros Pharmaceuticals (Inst)
 
William Jeffery Edenfield
Speakers' Bureau - Astellas Medivation; Novartis
 
Ursula A. Matulonis
Consulting or Advisory Role - 2X Oncology; Fujifilm; Geneos; Immunogen; Merck; Mersana; Myriad Genetics
Research Funding - Merck; Novartis; Syndax; Tesaro
 
Timothy F. Burns
Consulting or Advisory Role - Abbvie/Stemcentrx
 
Rebecca Mosher
Employment - Mersana; Novartis Institutes for BioMedical Research (I)
Stock and Other Ownership Interests - Mersana; Novartis Institutes for BioMedical Research (I)
Patents, Royalties, Other Intellectual Property - Mersana; Novartis Institutes for BioMedical Research (I)
 
Barbara Fielman
Employment - Boston Biomedical; Mersana
Stock and Other Ownership Interests - Mersana
 
Eric Hailman
Employment - Mersana
Stock and Other Ownership Interests - Mersana
 
Howard A. Burris
Employment - HCA Healthcare
Leadership - HCA Healthcare
Stock and Other Ownership Interests - HCA Healthcare
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); FORMA Therapeutics (Inst); Janssen (Inst); MedImmune (Inst); Mersana (Inst); Novartis (Inst); Roche/Genentech (Inst); TG Therapeutics (Inst)
Research Funding - Abbvie (Inst); Agios (Inst); AstraZeneca (Inst); Bayer (Inst); BioAtla (Inst); BioMed Valley Discoveries (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celldex (Inst); CicloMed (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); eFFECTOR Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Harpoon therapeutics (Inst); Immunocore (Inst); Incyte (Inst); Janssen (Inst); Jiangsu Hengrui Medicine (Inst); Jounce Therapeutics (Inst); Lilly (Inst); Loxo (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); Millennium (Inst); Moderna Therapeutics (Inst); Neon Therapeutics (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst); PTC Therapeutics (Inst); Regeneron (Inst); Revolution Medicines (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tesaro (Inst); TG Therapeutics (Inst); Valent Technologies (Inst); Verastem (Inst); Vertex (Inst)
Expert Testimony - Novartis
 
Kathleen N. Moore
Consulting or Advisory Role - Advaxis; Aravive; AstraZeneca; Clovis Oncology; Genentech/Roche; Immunogen; Janssen Oncology; Merck; OncoMed; Pfizer/EMD Serono; Samumed; TESARO; VBL Therapeutics
Speakers' Bureau - AstraZeneca
Research Funding - Abbvie/Stemcentrx (Inst); Advaxis (Inst); Agenus (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Forty Seven (Inst); Genentech (Inst); Immunogen (Inst); Lilly (Inst); Lilly Foundation (Inst); Merck (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Novogen (Inst); PTC Therapeutics (Inst); Regeneron (Inst); Stem CentRx (Inst); Takeda (Inst); Tesaro (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - Genentech/Roche
Other Relationship - AstraZeneca
 
Erika Paige Hamilton
Consulting or Advisory Role - Boehringer Ingelheim (Inst); Cascadian Therapeutics (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Flatiron Health; Genentech/Roche (Inst); Lilly (Inst); Mersana (Inst); Pfizer (Inst); Puma Biotechnology (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); ArQule (Inst); AstraZeneca (Inst); BerGenBio (Inst); Boehringer Ingelheim (Inst); Cascadian Therapeutics (Inst); Clovis Oncology (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); EMD Serono (Inst); Fujifilm (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Hutchison MediPharma (Inst); Immunomedics (Inst); InventisBio (Inst); Kadmon (Inst); Leap Therapeutics (Inst); Lilly (Inst); Lycera (Inst); Macrogenics (Inst); Mallinckrodt (Inst); MedImmune (Inst); Medivation (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Novartis (Inst); Nucana (Inst); OncoMed (Inst); Oncothyreon (Inst); Pfizer (Inst); PharmaMar (Inst); Radius Health (Inst); Regeneron (Inst); Rgenix (Inst); Stem CentRx (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TapImmune Inc. (Inst); Tesaro (Inst); TetraLogic Pharmaceuticals (Inst); Verastem (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Eisai; EMD Serono; Foundation Medicine; Genentech; Genentech/Roche; Genzyme; Guardant Health; Helsinn Therapeutics; HERON; Lexicon; Lilly; Lilly; Medivation; Merck; Novartis; Pfizer; Roche; Sysmex; Tesaro